Table I.
Correlation between EDNRB and clinicopathological data.
| EDNRB | EDNRB | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | HNCH number | Negative | Positive | P-value | OR | 95% CI | P | TCGA number | Negative | Positive | P-value | OR | 95% CI | P-value |
| Age | 0.01 | 3.37 | 1.28–8.87 | 0.01 | 0.62 | |||||||||
| <50 | 61 (61.6) | 52 (85.2) | 9 (14.8) | 50 (35.2) | 25 (50.0) | 25 (50.0) | ||||||||
| ≥50 | 38 (38.4) | 24 (63.2) | 14 (36.8) | 92 (64.8) | 42 (45.7) | 50 (54.3) | ||||||||
| Menopausal status | 0.02 | 0.78 | ||||||||||||
| Premenopausal | 60 (60.6) | 51 (85.0) | 9 (15.0) | 44 (31.0) | 20 (45.5) | 24 (54.5) | ||||||||
| Postmenopausal | 39 (39.4) | 25 (64.1) | 14 (35.9) | 98 (69.0) | 47 (48.0) | 51 (52.0) | ||||||||
| Tumor size, cm | 0.50 | 0.04 | 0.40 | 0.18–0.90 | 0.03 | |||||||||
| ≤2 | 33 (33.3) | 24 (72.7) | 9 (27.3) | 37 (26.1) | 12 (32.4) | 25 (67.6) | ||||||||
| >2 | 66 (66.7) | 52 (78.8) | 14 (21.2) | 105 (73.9) | 55 (52.4) | 50 (47.6) | ||||||||
| Pathological N stage | 0.23 | 0.01 | 4.30 | 1.33–13.89 | 0.02 | |||||||||
| 0-1 | 72 (72.7) | 53 (73.6) | 19 (26.4) | 123 (86.6) | 63 (51.2) | 60 (48.8) | ||||||||
| 2-3 | 27 (27.3) | 23 (85.2) | 4 (14.8) | 19 (13.4) | 4 (21.1) | 15 (78.9) | ||||||||
| NAC | 0.95 | |||||||||||||
| Yes | 35 (35.4) | 27 (77.1) | 8 (22.9) | |||||||||||
| No | 64 (64.6) | 49 (76.6) | 15 (23.4) | |||||||||||
HNCH, Henan Cancer Hospital; TCGA, The Cancer Genome Atlas; OR odds ratio; CI, confidence interval; N, lymph node; NAC, neoadjuvant chemotherapy; EDNRB, endothelin receptor B.